352 related articles for article (PubMed ID: 23818912)
1. Cellular mechanisms of multiple myeloma bone disease.
Oranger A; Carbone C; Izzo M; Grano M
Clin Dev Immunol; 2013; 2013():289458. PubMed ID: 23818912
[TBL] [Abstract][Full Text] [Related]
2. The multiple myeloma bone eco-system and its relation to oncogenesis.
Bataille R
Morphologie; 2015 Jun; 99(325):31-7. PubMed ID: 26005000
[TBL] [Abstract][Full Text] [Related]
3. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
4. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of myeloma bone disease.
Roodman GD
J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
[TBL] [Abstract][Full Text] [Related]
6. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
7. SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Heusschen R; Muller J; Binsfeld M; Marty C; Plougonven E; Dubois S; Mahli N; Moermans K; Carmeliet G; Léonard A; Baron F; Beguin Y; Menu E; Cohen-Solal M; Caers J
Oncotarget; 2016 May; 7(21):30712-29. PubMed ID: 27095574
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
[TBL] [Abstract][Full Text] [Related]
9. Tumor-host cell interactions in the bone disease of myeloma.
Fowler JA; Edwards CM; Croucher PI
Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
[TBL] [Abstract][Full Text] [Related]
10. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
Vallet S; Pozzi S; Patel K; Vaghela N; Fulciniti MT; Veiby P; Hideshima T; Santo L; Cirstea D; Scadden DT; Anderson KC; Raje N
Leukemia; 2011 Jul; 25(7):1174-81. PubMed ID: 21403648
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of bone disease in multiple myeloma: from bench to bedside.
Terpos E; Ntanasis-Stathopoulos I; Gavriatopoulou M; Dimopoulos MA
Blood Cancer J; 2018 Jan; 8(1):7. PubMed ID: 29330358
[TBL] [Abstract][Full Text] [Related]
12. Immunological reaction in TNF-α-mediated osteoclast formation and bone resorption in vitro and in vivo.
Kitaura H; Kimura K; Ishida M; Kohara H; Yoshimatsu M; Takano-Yamamoto T
Clin Dev Immunol; 2013; 2013():181849. PubMed ID: 23762085
[TBL] [Abstract][Full Text] [Related]
13. Osteoblast function in myeloma.
Roodman GD
Bone; 2011 Jan; 48(1):135-40. PubMed ID: 20601285
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
Giuliani N; Rizzoli V; Roodman GD
Blood; 2006 Dec; 108(13):3992-6. PubMed ID: 16917004
[TBL] [Abstract][Full Text] [Related]
15. [Osteoimmunology: how inflammation influences bone metabolism].
Lange U; Teichmann J; Schett G; Neumann E; Müller-Ladner U
Dtsch Med Wochenschr; 2013 Sep; 138(37):1845-9. PubMed ID: 24006167
[TBL] [Abstract][Full Text] [Related]
16. An Evidence-Based Approach to Myeloma Bone Disease.
Bingham N; Reale A; Spencer A
Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
[TBL] [Abstract][Full Text] [Related]
17. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
Dairaghi DJ; Oyajobi BO; Gupta A; McCluskey B; Miao S; Powers JP; Seitz LC; Wang Y; Zeng Y; Zhang P; Schall TJ; Jaen JC
Blood; 2012 Aug; 120(7):1449-57. PubMed ID: 22618707
[TBL] [Abstract][Full Text] [Related]
18. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
19. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
20. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
